Thursday, September 19, 2019 Pre-Conference Sessions

Friday, September 20, 2019

  • Friday Morning Pre-conference Sessions

  • Drugs and Genes: Pharmacogenomics for the Modern Health Care Team

  • Basic Science of Immunotherapy

  • Precision Cancer Care through Immunotherapy and Genomics

  • 1:15 PM

    Introduction and Welcome

    Dr. Bryce studies cancer genetics and novel therapeutics with a focus on personalized medicine. His clinical practice centers on genitourinary malignancies (prostate, kidney, bladder, and testicular cancers) and melanoma. He is the Medical Director of the Genomic Oncology Clinic at Mayo Clinic’s campus in Arizona where he utilizes whole genome sequencing of tumors to identify key driver mutations. This approach allows for precise targeting of a patient’s tumor, leading to a greater chance of remission. In addition, Dr. Bryce participates in community outreach to underserved populations and has an interest in health disparities research. He also conducts Phase I clinical trials of new cancer drugs. ...

  • 1:25 PM

    Past, Present and Future of Precision Medicine in Cancer Care

    Dr. Stewart conducts translational research in multiple myeloma. This includes both basic and clinical research to identify novel targets for therapy in multiple myeloma. His research can be divided into three broad categories: study of the cancer genome, cancer drug development, and clinical trials. His research is supported by the National Cancer Institute, Multiple Myeloma Research Foundation, and Leukemia & Lymphoma Society, as well as by partnerships with the pharmaceutical industry for clinical trials. In addition, Dr. Stewart serves as the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine. ...

  • 1:55 PM

    Keynote: CAR-T Therapy

  • 2:40 PM

    Under-diagnosis of Familial Cancer Syndromes and Faulty Clinical Guidelines

    Dr. Samadder’s focus is in the areas of hereditary cancer syndromes and endoscopic oncology. He directs the high risk cancer clinic at Mayo Clinic’s campus in Arizona, which provides genetic consultation and testing to patients with early onset cancer, rare cancers, and hereditary cancers. This practice provides clinical management to patients with an inherited cancer syndrome, including (but not limited to) those with Lynch syndrome, Familial Adenomatous Polyposis, MYH Associated Polyposis, Li Fraumeni syndrome, BRCA syndromes, or any other genetic cancer syndrome. This clinic provides patients with a single point of contact for genetic testing and cancer screenings. Dr. Samadder also leads multiple clinical trials using medications to prevent cancers in these patients. His efforts aim to increase genetic evaluation and testing of patients with cancer throughout Mayo Clinic. ...

  • 3:10 PM

    Questions and Discussion with the Faculty

  • 3:25 PM

    Refreshment Break

  • 3:40 PM

    Pharmacogenomics of Cancer drugs

    Dr. Weinshilboum studies pharmacogenomics — the role of inheritance and individual variation in DNA sequence or structure in drug response. His goal is to develop safer and more effective drug therapies to treat diseases ranging from cancer to depression. Dr. Weinshilboum’s research program uses genomic techniques including genome-wide association studies and “next-generation” whole genome DNA sequencing using samples from large numbers of patients treated with specific anti-cancer or anti-depressant drugs. His approach has already succeeded in the discovery and functional/mechanistic pursuit of new, unanticipated genes that influence response to a series of drugs used to treat childhood leukemia and breast cancer. Dr. Weinshilboum’s research has been continuously funded for decades by the National Institutes of Health and other foundation funding mechanisms. ...

  • 4:10 PM

    Genetic & Epigenetic Markers in RCC

  • 4:40 PM

    Evolutionary Biology of Tumors: Lessons from Pest Control and Ecology

    Dr. Maley is a biologist who specializes in cancer, evolution and computational biology and works at the intersection of these fields. He and his research team apply evolutionary and ecological theory to three problems in cancer. First, they investigate neoplastic progression: the evolutionary dynamics among cells of a tumor that drive progression from normal tissue to malignant cancers. Second, they examine acquired therapeutic resistance; the evolutionary dynamics by which therapies select for resistance and fail to cure cancer. Third, they look into the evolution of cancer suppression mechanisms in large, long-lived animals such as elephants and whales (a problem called Peto’s Paradox). His team uses genomic data mining, phylogenetics, computational modeling and wet lab techniques to solve these problems. In their work, the research team focuses on developing better methods to prevent cancer and improve cancer management. ...

  • 5:10 PM

    Questions and Discussion with the Faculty

  • 5:25 PM

    Summary of the Day

  • 5:40 PM

    Adjourn for Poster Session

  • 5:45 PM

    Poster Session and Welcome Reception

Saturday, September 21, 2019

  • Precision Cancer Care through Immunotherapy and Genomics (Continued)

    Precision Immunotherapy

  • 6:45 AM

    Continental Breakfast

  • 7:40 AM

    Introduction

    Dr. Anderson is a physician scientist with a joint appointment at Arizona State University and at Mayo Clinic’s campus in Arizona. She is a medical oncologist who focuses on biomarker development and immunotherapy in breast cancer and actively conducts clinical trials in these areas. Additionally, she has identified new targets for future breast cancer vaccine development using next-generation sequencing and high-throughput functional genomics. She obtained her M.D. and Ph.D. from Duke University School of Medicine and completed her internship and residency at the Brigham and Women’s Hospital.. ...

  • 7:50 AM

    Dendritic Cell Therapies

  • 8:10 AM

    Vaccines

    Dr. Knutson is an expert in the field of cancer immunology, specifically with regard to breast and ovarian cancers. He is involved in the clinical development and testing of self-tumor antigen-specific vaccines, and actively contributes to clinical trials and translation. He frequently authors high-impact journal articles and gives presentations on his research nationally and internationally. In recognition of his work, Dr. Knutson has received many awards and honors, including the Young Investigator Award-Pharmingen, conferred by the American Association for Cancer Research, and the prestigious Howard Temin Award, conferred by the National Institutes of Health, National Cancer Institute. He is also recognized as the 2017 Investigator of the Year at Mayo Clinic’s campus in Florida. Dr. Knutson has several current and past memberships with professional organizations which include the Breast Cancer Research Program and the Ovarian Cancer Research Program of the United States Department of Defense, the Tumor Microenvironment Study Section of the U.S. National Institutes of Health Center for Scientific Review, and the Education and Training Committee for the Society for the Immunotherapy of Cancer. He is a Principal Investigator of the Artemis Project, National Breast Cancer Coalition, where he is leading efforts to produce prevention vaccines for breast cancer. ...

  • 8:30 AM

    Immunotherapy in Lung Cancer

    Dr. Mansfield is a medical oncologist with a focus on thoracic malignancies and early therapeutics. He was the first to describe the negative prognostic significance of PD-L1 expression in mesothelioma and led the discovery that chromosomal rearrangements have neo-antigenic potential. He is the principal investigator of many clinical trials and translational projects evaluating the ability of blood-based biomarkers to predict responses to immunotherapy. In addition, Dr. Mansfield has helped lead accrual to the recent clinical trial that changed the practice of frontline therapy for patients with extensive stage small cell lung cancer. ...

  • 8:50 AM

    Questions and Discussion with the Faculty

  • 9:05 AM

    Issues in Cell Processing

    Dr. Stephan is a physician scientist at the Fred Hutchinson Cancer Research Center who works at the interface of materials science and immunology, designing synthetic materials that can be used as components of new cancer therapies that selectively modulate the immune system. His long-term goal is to make cancer immunotherapy more widely accessible and successful by creating off-the-shelf reagents that can rapidly boost the body's natural ability to fight cancer, moving synthetic immunomodulatory materials into routine clinical practice and shifting the treatment focus from broadly toxic chemotherapy and radical surgery to tumor-specific immunotherapies. Dr. Stephan demonstrated for the first time that immune T cells can be genetically engineered to self-stimulate when they encounter tumors, thereby enhancing anticancer immune responses. He also designed synthetic nanoparticles that can selectively deliver therapeutic drugs to tumors by smuggling them on the backs of tumor-seeking T cells, minimizing systemic drug toxicities. Currently, he continues to develop injectable nanoparticle reagents, including those that can rapidly program T cells to attack tumors. His ongoing research is focused on targeting melanoma, prostate, and ovarian cancers. ...

  • 9:25 AM

    CAR-T Cells for B Cell Lymphoma

  • 9:45 AM

    Refreshment Break

  • 10:05 AM

    Next Gen CAR Tcells / In Vivo CAR T-cells Using Nano Particle VectorsMatthias Stephan, M.D., Ph.D., Fred Hutchinson Cancer Center

  • 10:25 AM

    Escape Mechanism in CAR-T therapy / CAR-T for AML

    Dr. Gill is a physician scientist and assistant professor of medicine at the University of Pennsylvania where he specializes in the treatment of patients with leukemia. His research interests include tumor immunology, CAR T cells, mouse models of human leukemia, adoptive cell therapy, and flow cytometry. His most recent research examines the use of genetically modified T cells in the treatment and management of hematologic malignancies such as leukemia and lymphoma. His findings have also been applied to other diseases including neurodegenerative disorders. ...

  • 10:45 AM

    CAR-T Therapies for Lymphoma

    Dr. Castro has expertise in translational research and early-stage therapy development applied to hematologic malignancies with emphasis on cellular and stem cell therapy and gene immunotherapy. Dr. Castro focuses on translational research applied to the biology of cancer immunotherapy, discovery and optimization of novel antigens that can be used for cellular therapy, RNA splicing as a mechanism of gene and antigen diversity in cancer, and models of artificial intelligence applied to immunotherapy. His focus areas are cellular therapy for hematological cancer, cellular therapy for solid tumors, immune system response, early detection of side effects, and artificial intelligence and machine learning models applied in immuno-oncology. ...

  • 11:05 AM

    Overview of CAR-T ToxicitiesMarco L. Davila, M.D., Ph.D., Moffitt

  • 11:25 AM

    Clinical Management of Immune ToxicitiesLisa Kottschade, APRN, CNP, Mayo Clinic

  • 11:45 AM

    Questions and Discussion with the Faculty

  • 12:00 PM

    Lunch

  • Genomic Oncology

  • 1:00 PM

    Applying Genomic Profiling to Breast Cancer

    Dr. Liu is a medical oncologist and translational researcher in the Department of Oncology and Department of Laboratory Medicine and Pathology at Mayo Clinic. Her clinical practice focuses on providing care to patients with breast cancer. Her laboratory interests focus on the development and implementation of blood-based biomarkers for all solid tumors. She leads several studies with clinical and correlative endpoints focused on the efficient development of reliable predictors of treatment outcomes. ...

  • 1:20 PM

    Beyond EGFR, ALK, and ROS1: Applying NGS to Lung Cancer

  • 1:40 PM

    Treatment Implications of Molecular Variation in Prostate Cancer

    Dr. Himisha Beltran is a medical oncologist and physician scientist at the Dana Farber Cancer Institute. Her clinical and research interests are in the areas of prostate cancer and precision oncology. Her lab has focused on understanding mechanisms of treatment resistance in advanced prostate cancer and has developed therapeutic targets and biomarkers for non-androgen receptor driven prostate cancer including neuroendocrine prostate cancer, an aggressive subtype of castration resistant prostate cancer. As recent Director of Clinical and Translational Research within the Weill Cornell Englander Institute for Precision Medicine (2013-2018) and now as newly appointed Director of Translational Research in Medical Oncology at the DFCI, Dr. Beltran works to develop molecularly based treatment approaches for patients including through the establishment of protocols for metastatic biospecimen collection, serial blood collection, and the use of next generation molecular assays. She has led the development and characterization of patient-derived tumor models including prostate cancer organoids and PDXs. She has also helped develop genomic and other molecular assays for clinical trials including a circulating tumor DNA platform for prostate cancer. ...

  • 2:00 PM

    Questions and Discussion with the Faculty

  • 2:20 PM

    Genetic Analysis in Myeloid Malignancies

    Dr. Patnaik is a hematologist with significant interest in myeloid neoplasms, especially myelodysplastic syndromes and chronic myelomonocytic leukemia. His research is centered on understanding epigenetic and chromatin dysregulation in patients with chronic myelomonocytic leukemia. Dr. Patnaik studies transcriptional abnormalities produced in these patients secondary to mutations in epigenetic regulator genes such as TET2, ASXL1, and EZH2. Dr. Patnaik has received many honors and awards during his career including the Arnold P. Gold Foundation Award for Humanism and Excellence in Teaching (2007), Jeevan Paul Humanitarian Award (2008), Best Diagnostician Award (2008), Celgene Future Leader in Hematology Award (2010), Mayo Fellows Association Teacher of the Year Award (2012), Outstanding Young Investigator Hematology-Oncology (2015), and Mayo Fellows Association Teacher of the Year Award—Induction into the Hall of Fame (2018). ...

  • 2:40 PM

    Precision Therapy in Hematologic MalignanciesJeffrey W. Tyner, Ph.D., OHSU

  • 3:00 PM

    Questions and Discussion with the Faculty

  • 3:15 PM

    Refreshment Break

  • 3:35 PM

    NCI MATCH and COMBO MATCHFunda Meric-Bernstam, M.D., MD Anderson

  • 3:55 PM

    Lessons from Melanoma: Target Discovery and Novel Therapeutics

    Dr. Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on immune checkpoint blockade, gene engineered T cells, and BRAF targeted therapies at the University of California, Los Angeles. He has had a leading role in the clinical development and FDA approval of five new drugs for the treatment of metastatic melanoma. His National Cancer Institute, State of California and foundation-supported research laboratory develops models of disease to test new therapeutic options, studies mechanism of action of treatments in patients and the molecular mechanisms of therapy resistance. This work has allowed defining mechanisms of response and resistance to modern immunotherapies.

    Dr. Ribas is an elected member of the American Society of Clinical Investigation, has a Doctor Honoris Causa from the University of Buenos Aires, co-led the Stand Up to Cancer -Cancer Research Institute -AACR Immunotherapy Dream Team with the Nobel Laureate James Allison, is the recipient of a NCI Outstanding Investigator Award, was profiled as one of the five Visionaries in Medicine by the New York Times on May 27, 2018, acknowledged as Great Immigrant by the Carnegie Foundation in the New York Times on July 4, 2018, and is the recipient of the 2014 AACR Richard and Hinda Rosenthal Award and the 2018 AACR-CRI Lloyd J. Old Award in Cancer Immunology. He currently serves as Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles, Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center, Director of the Parker Institute for Cancer Immunotherapy Center at UCLA, Chair of the Melanoma Committee at SWOG, and President-elect of the America Association for Cancer Research.
    ...

  • 4:15 PM

    Biliary Cancer: Transforming Rare Tumor Therapy through Target Discovery

    Dr. Borad is an Associate Professor of Medicine and Director of Phase I Drug Development at Mayo Clinic Arizona. His research and clinical interests are in biomarker discovery and precision medicine for patients with biliary and liver cancers. Using whole genome analysis, his team works on discovery of new drug targets and delivery of precision medicine for patients with cholangiocarcinoma. Dr. Borad obtained his internal medicine training at Cedars-Sinai Medical Center and completed his medical oncology fellowship at Tulane University School of Medicine. ...

  • 4:35 PM

    Tumor Profiling by Cell Free DNA

  • 4:55 PM

    Questions and Discussion with the Faculty

  • 5:15 PM

    Educational Summary with the Moderator

  • 5:30 PM

    Adjourn

Sign Up for Updates Receive information about our 2019 conference speakers, schedule and registration.

Contact For more information about Individualizing Medicine 2019:
Email: imconference@mayo.edu

Give Hope

The Center for Individualized Medicine is a strategic priority for the Campaign for Mayo Clinic.